Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method for targeting Hepatic Stellate Cells (HSC) ~~cells~~ involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, in a tissue sample of a subject using a carrier molecule, said carrier molecule being linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC.

Claim 2 (currently amended): A method for targeting Hepatic Stellate Cells (HSC) ~~cells~~ involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, in a subject using, in a pharmaceutically acceptable amount and form, a carrier molecule, said carrier molecule being linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC.

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (previously presented): A method according to claim 1 or 2, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 6 (previously presented): A method according to claim 1 or 2, wherein the carrier molecule comprises a diagnostic marker attached thereto.

Claim 7 (currently amended): A method according to claim 1 or 2, wherein the sclerotic or fibrotic disease is ~~cells involved in a sclerotic and/or a fibrotic disease are cells~~

~~involved in a disease selected from the group consisting of~~ liver fibrosis ~~, kidney fibrosis, lung fibrosis, atherosclerosis and chronic or acute inflammatory processes such as rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis, sepsis and tumor-cell proliferation associated pathology, fibroblast proliferation associated pathology, endothelial cell proliferation associated pathology and osteoblast proliferation associated pathology~~.

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12 (canceled)

Claim 13 (canceled).

Claim 14 (currently amended): A compound ~~for targeting cells involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, wherein said compound comprises~~ comprising a carrier molecule linked to at least one further molecule, said further molecule comprising a cyclic peptide wherein the cyclic portion of said cyclic peptide comprises the amino acid sequence ~~being X*~~SRNLIDC~~X*~~, ~~wherein X* represents the location of cyclisation~~.

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (currently amended): A compound according to claim 14, wherein in ~~of~~ the further molecule, the cyclic portion of the cyclic peptide comprises multiple receptor binding sequences.

Claim 19 (currently amended): A compound according to claim 14, wherein in ~~of~~ the further molecule, the cyclic portion of the cyclic peptide comprises multiple receptor binding sequences directed at at least two different types of receptors.

Claim 20 (previously presented): A compound according to claim14, wherein the further molecule comprises multiple cyclic peptides directed at the same or different types of receptors.

Claim 21 (previously presented): A compound according to claim 14, wherein the carrier molecule is selected from the group of carrier molecules consisting of proteins, oligo or polypeptides, immunoglobulins or parts thereof, oligonucleotides, disaccharides, polysaccharides, biodegradable synthetic polymers, liposomes, lipid particles, biocompatible polymers in the form of microspheres or nanoparticles, endogenous plasma proteins, lactoferrin, alkaline phosphatase, superoxide dismutase, alpha2 macroglobulin and fibronectin.

Claim 22 (previously presented): A compound according to claim 14, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 23 (previously presented): A compound according to claim 14, wherein the carrier molecule comprises a diagnostic marker attached thereto.

Claim 24 (currently amended): A pharmaceutical composition comprising a compound according to any one of claims 14 or ~~16-23~~ 18-23 as targeting ingredient and one or more pharmaceutically acceptable carriers.

Claim 25 (currently amended): A method of using a compound according to any one of claims 14 or ~~16-23~~ 18-23 for in vitro diagnosis of ~~a sclerotic and/or fibrotic disease selected from the group consisting of~~ liver fibrosis[[,]] or kidney fibrosis~~, lung fibrosis, atherosclerosis and chronic or acute inflammatory processes, Crohns disease, colitis ulcerosa, glomerulonephritis, sepsis and tumor-cell proliferation associated pathology, fibroblast proliferation associated pathology, endothelial cell proliferation associated pathology and osteoblast proliferation associated pathology~~.

Claim 26 (currently amended): A method of using a compound according to any one of claims 14 or ~~16-23~~ 18-23 for the preparation of a medicament for in vivo diagnosis, prophylaxis and/or therapy ~~of a sclerotic and/or fibrotic disease selected from the group consisting of~~ liver fibrosis[[,]] or kidney fibrosis~~, lung fibrosis, atherosclerosis and chronic or acute inflammatory processes, Crohns disease, colitis ulcerosa, glomerulonephritis, sepsis and tumor-cell proliferation associated pathology, fibroblast proliferation associated pathology, endothelial cell proliferation associated pathology and osteoblast proliferation associated pathology~~.

Claim 27 (canceled).

Claim 28 (original): Method according to claim 21, wherein said endogenous plasma protein is albumin.

Claim 29 (currently amended): Method according to claim 25, wherein said liver fibrosis is cirrhosis, or wherein said kidney fibrosis is glomerulosclerosis or interstitial fibrosis~~, or wherein said chronic or acute inflammatory process is rheumatoid arthritis~~.

Claim 30 (currently amended): Method according to claim 26, wherein said liver fibrosis is cirrhosis, or wherein said kidney fibrosis is glomerulosclerosis or interstitial fibrosis~~, or wherein said chronic or acute inflammatory process is rheumatoid arthritis~~.

Claim 31 (new): A method for targeting cells involved in sclerotic and/or fibrotic diseases selected from liver fibrosis and kidney fibrosis, and in which cells the PDGF-receptor is upregulated during said disease, in a tissue sample of a subject using a carrier molecule, said carrier molecule linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC, wherein said liver fibrosis is liver cirrhosis and said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

Claim 32 (new): A method for targeting cells involved in sclerotic and/or fibrotic diseases selected from liver fibrosis and kidney fibrosis, and in which cells the PDGF-receptor is upregulated during said disease, in a subject using, in a pharmaceutically acceptable amount and form, a carrier molecule, said carrier molecule linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC and wherein said liver fibrosis is liver cirrhosis and wherein said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

Claim 33 (new): A method according to claim 31 or 32, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 34 (new): A method according to claim 31 or 32, wherein the carrier molecule comprises a diagnostic marker attached thereto.